Core Viewpoint - Haisheng Pharmaceutical reported significant growth in revenue and net profit for the third quarter of 2025, driven by increased sales, improved bank investment returns, and government subsidies [1] Financial Performance - The company achieved operating revenue of 164 million yuan, representing a year-on-year increase of 40.89% [1] - The net profit attributable to shareholders reached 49.05 million yuan, up 47.16% year-on-year [1] - In the third quarter alone, the net profit attributable to shareholders was 18.72 million yuan, showing a remarkable growth of 89.48% compared to the same period last year [1] Investment and Assets - The company's construction in progress increased by 45.40% compared to the beginning of the year, primarily due to investments in new production lines, laying a foundation for future development [1] - A decrease in cash holdings was noted, attributed to the purchase of large bank financial products, with trading financial assets at the end of the period amounting to 360 million yuan [1]
海昇药业：第三季度归母净利润同比增长89.48%